Active Not RecruitingNCT07076407
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Researchers are comparing Azetukalner and placebo to find out how the approaches affect depression symptoms in people with depression.
Medication studyAges 18–74Multiple countries
Understand this study
What is this study about?
Researchers are comparing Azetukalner and placebo to find out how the approaches affect depression symptoms in people with depression.
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- Dothan and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 8, 2025
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 450
- Sponsor
- Xenon Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Finland, Germany, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT07076407
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Recruitment & locations
Not recruitingDothan, United States · Huntsville, United States · Bentonville, United States
43 more locations
- Bryant, United States
- Bellflower, United States
- La Jolla, United States
- San Diego, United States
- Sherman Oaks, United States
- Upland, United States
- Hartford, United States
- Fort Myers, United States
- Gainesville, United States
- Riverview, United States
- Atlanta, United States
- Orland Park, United States
- Jefferson, United States
- Baltimore, United States
- Boston, United States
- Methuen, United States
- Watertown, United States
- Worcester, United States
- O'Fallon, United States
- Saint Charles, United States
- Cherry Hill, United States
- Princeton, United States
- Toms River, United States
- Mount Kisco, United States
- New York, United States
- Cary, United States
- Independence, United States
- Oklahoma City, United States
- Austin, United States
- Provo, United States
- Helsinki, Finland
- Oulu, Finland
- Berlin, Germany
- Rosenheim, Germany
- Bydgoszcz, Poland
- Katowice, Poland
- Poznan, Poland
- Bucharest, Romania
- Craiova, Romania
- Banská Bystrica, Slovakia
- Liptovský Mikuláš, Slovakia
- Barcelona, Spain
- Palma de Mallorca, Spain
A listed location does not confirm current availability.
About the molecule
When a study medicine is clearly identified, HopeStage adds a short explanation of what that molecule is and links back to reliable public sources.
Azetukalner
an experimental Kv7 potassium-channel opener
targets Kv7 potassium channels
Questions about this study
What is this study about?
Researchers are comparing Azetukalner and placebo to find out how the approaches affect depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Xenon Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including Azetukalner and Placebo.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
